How has ADMA Biologics's accrued expenses and other liabilities changed year-over-year?

ADMA Biologics's accrued expenses and other liabilities increased by 53.9% year-over-year, from $31.56M to $48.56M.

What is the long-term trend for ADMA Biologics's accrued expenses and other liabilities?

Over 5 years (2020 to 2025), ADMA Biologics's accrued expenses and other liabilities has grown at a 37.1% compound annual growth rate (CAGR), from $8.37M to $40.47M.

ADMA Biologics ADMA Accrued expenses and other liabilities

Accrued expenses and other liabilities at other companies

DigitalBridge GroupDBRG

$615.37M-9.2%

ImaxIMAX

$88.14M-4.9%

Century CommunitiesCCS

$276.77M-3.3%

Affirm Holdings, Inc.AFRM

$217.94M+25.5%

UBS

United BanksharesUBSI

$267.01M+5.0%

Upstart Holdings, Inc.UPST

$124.59M+58.4%

Other financials

Income statement

See full

Revenue$114.5M-0.3%

Gross profit$80.8M+32.2%

Operating income$58.3M+67.1%

Net income$45.3M+68.5%

EPS (diluted)$0.19+72.7%

Balance sheet

See full

Cash & equivalents$138.2M+92.9%

Total debt$204.4M+2,055%

Total equity$390.3M+4.5%

Total assets$665.2M+30.3%

Cash flow

See full

Operating cash flow$58.2M+396%

CapEx$2.5M-45.9%

Free cash flow$55.7M+329%

Valuation

See full

Market cap$2.01B-54.5%

Enterprise value$2.08B-52.5%

P/E12.2×-9.2×

P/S4×-5.7×

Profitability

See full

Gross margin61.3%+8.7pp

Operating margin42.1%+9.0pp

Net margin32.4%-12.6pp

FCF margin21.2%+1.4pp

Returns & leverage

See full

Return on equity43.3%-35.2pp

Debt / equity0.5×+0.5×

Current ratio7×+0.4×

Where this comes from

Reported directly by ADMA Biologics in its filing.

Tagged under the XBRL concept us-gaap:AccruedLiabilitiesAndOtherLiabilities.

The official record: ADMA Biologics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about ADMA Biologics's accrued expenses and other liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is ADMA Biologics's accrued expenses and other liabilities?: ADMA Biologics (ADMA) reported accrued expenses and other liabilities of $48.56M in Q1 2026.
How has ADMA Biologics's accrued expenses and other liabilities changed year-over-year?: ADMA Biologics's accrued expenses and other liabilities increased by 53.9% year-over-year, from $31.56M to $48.56M.
What is the long-term trend for ADMA Biologics's accrued expenses and other liabilities?: Over 5 years (2020 to 2025), ADMA Biologics's accrued expenses and other liabilities has grown at a 37.1% compound annual growth rate (CAGR), from $8.37M to $40.47M.